Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Finished Goods: 2023-2025

Historic Finished Goods for Phathom Pharmaceuticals (PHAT) over the last 2 years, with Sep 2025 value amounting to $2.6 million.

  • Phathom Pharmaceuticals' Finished Goods rose 137.93% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 137.93%. This contributed to the annual value of $1.5 million for FY2024, which is 128.59% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Finished Goods of $2.6 million as of Q3 2025, which was up 6.68% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Finished Goods peaked at $2.6 million during Q3 2025, and registered a low of $647,000 during Q4 2023.
  • For the 3-year period, Phathom Pharmaceuticals' Finished Goods averaged around $1.5 million, with its median value being $1.3 million (2024).
  • Data for Phathom Pharmaceuticals' Finished Goods shows a peak YoY surged of 177.27% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Phathom Pharmaceuticals' Finished Goods stood at $647,000 in 2023, then soared by 128.59% to $1.5 million in 2024, then spiked by 137.93% to $2.6 million in 2025.
  • Its Finished Goods stands at $2.6 million for Q3 2025, versus $2.4 million for Q2 2025 and $1.7 million for Q1 2025.